Gossamer Bio (4GB0) AI Stock Analysis

10 Followers

Gossamer Bio

(Frankfurt:4GB0)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Regulatory progressSubmitting the first NDA moves seralutinib from late-stage development into formal FDA review, creating a defined regulatory pathway for the lead asset. If the application is accepted and approved, Gossamer could transition toward commercialization in PAH and establish a larger strategic base.

Negative Factors

Persistent cash burnHeavy operating and free cash flow losses show that the company is not yet self-funding its activities and remains dependent on external capital. Persistent burn can reduce financial flexibility, increase financing needs, and make execution more sensitive to regulatory or development delays.

Gossamer Bio (4GB0) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 71.43M
Dividend Yield: ―
Average Volume (3M): 60
Price to Earnings (P/E): -0.3
Beta (1Y): 0.09
Revenue Growth: 70.52%
EPS Growth: 38.03%
Country: Germany
Employees: 162
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Gossamer Bio Business Overview & Revenue Model

Company Description

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an...

Gossamer Bio Risk Analysis

Gossamer Bio disclosed 80 risk factors in its most recent earnings report. Gossamer Bio reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk

1.We have obtained stockholder approval to effect a reverse stock split of our common stock at a ratio ranging from 1-for-10 and 1-for-150, which if implemented may have adverse effects on our common stock.Q2, 2026

Gossamer Bio Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:4GB0 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALEC	55Neutral	$376.66M	7.51	112.21%	―	151.23%	―
CNTB	52Neutral	$42.96M	-1.27	-94.11%	―	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALDX	42Neutral	$37.97M	-2.04	>-0.01%	―	―	56.04%
CUE	34Underperform	$136.28M	-0.69	-1032.19%	―	354.37%	-63.33%

* Healthcare Sector Average

Performance Comparison

DE:4GB0 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:4GB0	Gossamer Bio	8.84	-170.84	-95.08%
ALDX	Aldeyra Therapeutics	0.65	-4.37	-87.03%
CUE	Cue Biopharma	18.66	0.07	0.39%
TLSA	Tiziana Life Sciences (US)	0.62	-1.03	-62.36%
ALEC	Alector	2.63	1.43	119.17%
CNTB	Connect Biopharma Holdings Ltd.	0.69	-0.99	-59.05%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Gossamer Bio AI Stock Analysis